Listed as an open Gladiator cash-segment Buy call with recommendation range 960-985, target 1108 and stoploss 911 over 3 months.
Read this note →Supriya Lifescience Limited
NSE SUPRIYA BSE 543434 INE07RO01027
0 filings · 0 analysed
631.25
-11.98%
over 6 months
-
Listed as an open Gladiator cash-segment Buy call with recommendation range 960-985, target 1108 and stoploss 911 over 3 months.
-
The note lists the stock as a 'Buy' under its three-month duration product recommendations without stated levels in this document.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| ICICI Securities Limited (ICICI Direct Research, Retail Research) | 07 Oct 2026, 08:41 | long | 889.25 | 1,108.00 | 695.80 | -88% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The note lists the stock as a 'Buy' under its three-month duration product recommendations without stated levels in this document.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief